Total medical devices industry venture financing deals in April 2019 worth $649.3m were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 33% over the previous month and a drop of 12.1% when compared with the last 12-month average, which stood at $739.03m.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $519.55m. At the country level, the US topped the list in terms of deal value at $473.86m.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of venture financing deals activity in April 2019 was the US with 52 deals, followed by China with five and Canada with four.
In 2019, as of the end of April 2019, medical devices venture financing deals worth $2.83bn were announced globally, marking a decrease of 18.8% year on year.
Medical devices industry venture financing deals in April 2019: Top deals
The top five medical devices industry venture financing deals accounted for 39.9% of the overall value during April 2019.
The combined value of the top five medical devices industry venture financing deals stood at $259.16m, against the overall value of $649.3m recorded for the month. The top announced medical devices industry venture financing deal tracked by GlobalData in April 2019 was Ally Bridge Group, ArrowMark Partners, Driehaus Capital Management and RTW Investments’ $65m venture financing of Pulmonx.
In second place was the $60m venture financing of PathAI by General Atlantic and General Catalyst Partners and in third place was Fred Moll, Johnson & Johnson Innovation – JJDC, Lumira Capital Investment Management, State of Wisconsin Investment Board, Varian Medical Systems and Venture Investors‘ $54m venture financing of HistoSonics.
The $44.66m venture financing of Creative Biosciences (Guangzhou) by CDH Investments Fund Management and IDG Capital and Aperture Venture Partners, Aphelion Capital, Ascension Ventures, Healthcare Enterprise, HealthQuest Capital, Lumira Capital Investment Management, Rex Health Ventures, River Cities Capital Funds and SV Health Investors‘ venture financing of BardyDx for $35.5m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.